New anxiety medications in development -  Part 3: BNC210

New anxiety medications in development – Part 3: BNC210

Of the few new and promising anxiety medications under development, BNC210, one of the anxiolytic medicines, has demonstrated a potent anxiolytic effect. Although the trials of this medication are still under way, it has shown efficacy in suppressing the malfunctioning areas of the brain that are responsible for anxiety.

Since it has no addictive or sedative properties, many believe that it can prove to be a better drug in managing anxiety than the current best lorazepam (a benzodiazepine medication). Moreover, it is unlikely to affect the cognitive function due to above characteristics. So far, no major side effect has been reported during the trials.

Bionomics, an Australian biotech company focusing on creating therapies for the central nervous system (CNS) disorders, has successfully tested the medicine in the phase 2 trials. During the phase 2 trials, the medicine successfully suppressed anxiety-related defensive behavior and even outperformed lorazepam.

In the first two articles of this series, “New anxiety medications in development,” the effectiveness of new anxiety medications, such as Aloradine and B-GOS, was discussed. The current article discusses in detail about BNC210 and its role in the fight against anxiety. In fact, many researchers have hailed the medicine with the potential to bring forth paradigm shift in the treatment of anxiety disorders.

Understanding the antidepressant effects of BNC210

According to Bionomics, BNC210 is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, which is a novel target for anxiety. Chemically, it is known as L-Isoleucyl-L-tryptophan, which has a chemical formula C17H23N3O3. 

It displays an antidepressant effect without causing physical dependence. Although further information about its application and form have not been made public yet, its major effect will be on the central nervous system (CNS) for treating serious mental disorders, such as generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).

According to Dr. Adam Perkins, Lecturer, Neurobiology of Personality, King’s College London, who was involved in the testing of the drug, “BNC210 engages anxiety-related brain systems more effectively than lorazepam. Moreover, the neuroimaging results were backed up by the behavioral findings, as BNC210 also reduced the intensity of threat avoidance behavior to a significant degree, once again outperforming lorazepam.”

In the comparative study with lorazepam, it was found that BNC210 changed the cerebral perfusion (a high flow, low-pressure system with an almost constant diastolic flow in the brain). BNC210 also significantly reduced amygdala activation in response to fearful faces during the Emotional Faces Task (EFT). As amygdala plays a crucial role in the management of the fear and anxiety related responses, BNC210 affects patients with anxiety disorder by suppressing amygdala activation.

One of the main characteristic features of anxiety and fear are the responses generated in the brain. As fear or anxiety often causes a range of defensive behaviors, these major bottlenecks disrupts the day-to-day life of the patients. However, the administration of BNC210 significantly decreases the intensity of threat avoidance behavior. This means that BNC210 has a positive effect on the responses generated in the brain, which can diminish anxiety and fear that arise during GAD.

Generally, stopping the current antidepressant medications often cause a series of withdrawal symptoms, which highlights the increased physical dependence of the patient on the drug. However, a BNC210 test on rats showed no symptoms of withdrawal symptoms or physical dependence. This can prove significantly beneficial because side effects often make the treatment ineffective in the long run.

A new hope for many sufferers

Overall, approximately 40 million adults have anxiety in the U.S. and out of these, an estimated 6.8 million suffer from GAD, highlights the Anxiety and Depression Association of America (ADAA). BNC210 can be a new ray of hope for these patients. In fact, BNC210 can be a great medication to be used in the GAD treatment centers in California.

If you or any of your loved one is suffering from anxiety disorder, connect to the Anxiety Treatment Centers of California. Call us at our 24/7 helpline number 855-972-9459 or chat online to get help in finding excellent anxiety disorders treatment centers in California.

Read the other parts of the series, “New anxiety medications in development:”

Part 1: Aloradine

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply